Mirae Asset Global Etfs Holdings Ltd. Viridian Therapeutics, Inc.\De Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 41,798 shares of VRDN stock, worth $902,418. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,798
Previous 49,276
15.18%
Holding current value
$902,418
Previous $664,000
12.05%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$116 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$105 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$103 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$97.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$95.6 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $861M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...